Literature DB >> 22209916

Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States.

Masaki Yamada1, Richard Buller, Stephanie Bledsoe, Gregory A Storch.   

Abstract

Macrolide-resistant Mycoplasma pneumoniae is widespread in Asia, and severe cases of pneumonia have been described in children. Little information is available about the resistance pattern in the United States. We collected respiratory samples from 49 patients with Mycoplasma infection in the central United States between 2007 and 2010. We found a macrolide resistance rate of 8.2%. Resistance should be considered when patients with M. pneumoniae infection do not have a satisfactory response to macrolides. Alternative antibiotics include tetracyclines or fluoroquinolones.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22209916     DOI: 10.1097/INF.0b013e318247f3e0

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  38 in total

1.  In vitro subminimum inhibitory concentrations of macrolide antibiotics induce macrolide resistance in Mycoplasma pneumoniae.

Authors:  G Ou; Y Liu; Y Tang; X You; Y Zeng; J Xiao; L Chen; M Yu; M Wang; C Zhu
Journal:  Hippokratia       Date:  2015 Jan-Mar       Impact factor: 0.471

2.  Detection and characterization of Mycoplasma pneumoniae during an outbreak of respiratory illness at a university.

Authors:  Jessica L Waller; Maureen H Diaz; Brianna L Petrone; Alvaro J Benitez; Bernard J Wolff; Laura Edison; Melissa Tobin-D'Angelo; Ashley Moore; Audrey Martyn; Hope Dishman; Cherie L Drenzek; Kim Turner; Lauri A Hicks; Jonas M Winchell
Journal:  J Clin Microbiol       Date:  2013-12-26       Impact factor: 5.948

Review 3.  Mycoplasma pneumoniae from the Respiratory Tract and Beyond.

Authors:  Ken B Waites; Li Xiao; Yang Liu; Mitchell F Balish; T Prescott Atkinson
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

4.  Multilocus variable-number tandem-repeat analysis-confirmed emergence of a macrolide resistance-associated mutation in Mycoplasma pneumoniae during macrolide therapy for interstitial pneumonia in an immunocompromised child.

Authors:  Sébastien Hantz; Fabien Garnier; Olivia Peuchant; Céline Menetrey; Alain Charron; Marie-Cécile Ploy; Cécile Bébéar; Sabine Pereyre
Journal:  J Clin Microbiol       Date:  2012-07-18       Impact factor: 5.948

5.  Low rate of macrolide resistance in Mycoplasma pneumoniae strains in Germany between 2009 and 2012.

Authors:  Roger Dumke; Christian Lück; Enno Jacobs
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

6.  Structural Study of MPN387, an Essential Protein for Gliding Motility of a Human-Pathogenic Bacterium, Mycoplasma pneumoniae.

Authors:  Yoshito Kawakita; Miki Kinoshita; Yukio Furukawa; Isil Tulum; Yuhei O Tahara; Eisaku Katayama; Keiichi Namba; Makoto Miyata
Journal:  J Bacteriol       Date:  2016-08-11       Impact factor: 3.490

7.  NLRP3 Is a Critical Regulator of Inflammation and Innate Immune Cell Response during Mycoplasma pneumoniae Infection.

Authors:  Jesus A Segovia; Te-Hung Chang; Vicki T Winter; Jacqueline J Coalson; Marianna P Cagle; Lavanya Pandranki; Santanu Bose; Joel B Baseman; Thirumalai R Kannan
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

8.  Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program.

Authors:  K B Waites; A Ratliff; D M Crabb; L Xiao; X Qin; R Selvarangan; Y-W Tang; X Zheng; J Dien Bard; T Hong; M Prichard; E Brooks; S Dallas; L Duffy; E Mixon; K B Fowler; T P Atkinson
Journal:  J Clin Microbiol       Date:  2019-10-23       Impact factor: 5.948

9.  Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients.

Authors:  Yasuhiro Kawai; Naoyuki Miyashita; Mika Kubo; Hiroto Akaike; Atsushi Kato; Yoko Nishizawa; Aki Saito; Eisuke Kondo; Hideto Teranishi; Satoko Ogita; Takaaki Tanaka; Kozo Kawasaki; Takashi Nakano; Kihei Terada; Kazunobu Ouchi
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

10.  Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients.

Authors:  Yasuhiro Kawai; Naoyuki Miyashita; Mika Kubo; Hiroto Akaike; Atsushi Kato; Yoko Nishizawa; Aki Saito; Eisuke Kondo; Hideto Teranishi; Tokio Wakabayashi; Satoko Ogita; Takaaki Tanaka; Kozo Kawasaki; Takashi Nakano; Kihei Terada; Kazunobu Ouchi
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.